|
Biosimilar medicines have delivered 18BN€ total savings for Europe but more action needed to translate this potential into patient access and sustainable health systems |
Medicines for Europe |
16 Dec 2021 |
Health & Consumers |
|
Commission study highlights market framework conditions are main driver for medicines shortages |
Medicines for Europe |
10 Dec 2021 |
Health & Consumers |
|
Access to essential medicines threatened by combination of increasing inflation and potential further price cuts in EU countries |
Medicines for Europe |
26 Nov 2021 |
Health & Consumers |
|
European Parliament report calls for increased use of off-patent medicines to improve patient access |
Medicines for Europe |
25 Nov 2021 |
Health & Consumers |
|
The EU must stop the offshoring of essential medicines manufacturing investments: ambitious, open and coherent policies must support competitive, robust and sustainable production of APIs and medicines |
Medicines for Europe |
23 Nov 2021 |
Global Europe |
|
Adjustments to IP framework needed to improve access to medicines in Europe |
Medicines for Europe |
16 Nov 2021 |
Science & Policymaking |
|
Access to medicines critical in European Parliament vote on EU IP action plan |
Medicines for Europe |
12 Nov 2021 |
Health & Consumers |
|
EU must learn from Covid-19 to improve crisis preparedness and response for the future |
Medicines for Europe |
09 Nov 2021 |
Health & Consumers |
|
European Commission pilot project on repurposing brings value added innovation to life |
Medicines for Europe |
28 Oct 2021 |
Health & Consumers |
|
Baton passes from Christoph Stoller to Rebecca Guntern as President of Medicines for Europe |
Medicines for Europe |
01 Oct 2021 |
Health & Consumers |
|
HERA must address outstanding weaknesses in EU pharma framework to be successful |
Medicines for Europe |
16 Sep 2021 |
Health & Consumers |
|
Orphan and paediatric reform should strive to improve access to medicine for rare disease patients and children |
Medicines for Europe |
30 Jul 2021 |
Health & Consumers |
|
EU must take the lead to ensure security of supply for medicines |
Medicines for Europe |
16 Jun 2021 |
Health & Consumers |
|
Open borders that prioritise essential goods key to medicines supply in Europe |
Medicines for Europe |
02 Jun 2021 |
Health & Consumers |
|
EU Industrial strategy should be key to improving medicines supply chains |
Medicines for Europe |
17 May 2021 |
Health & Consumers |
|
Off patent medicines essential for a fairer, healthier, and sustainable Europe says President Christoph Stoller |
Medicines for Europe |
30 Apr 2021 |
Health & Consumers |
|
European patients need improved access to biosimilar medicines |
Medicines for Europe |
22 Apr 2021 |
Health & Consumers |
|
New report assesses progress on biosimilar medicine policies across Europe |
Medicines for Europe |
30 Mar 2021 |
Health & Consumers |
|
EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply |
Medicines for Europe |
17 Mar 2021 |
Health & Consumers |
|
New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability |
Medicines for Europe |
01 Mar 2021 |
Health & Consumers |
|
Smart policies will encourage more critical medicines manufacturing in Europe |
Medicines for Europe |
26 Feb 2021 |
Health & Consumers |
|
EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare |
Medicines for Europe |
23 Feb 2021 |
Health & Consumers |
|
A new medicines trade and health security agenda for the European Commission |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
No further excuse to delay digital regulatory infrastructure for medicines after COVID-19 pandemic |
Medicines for Europe |
19 Feb 2021 |
Health & Consumers |
|
Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care |
Medicines for Europe |
04 Feb 2021 |
Health & Consumers |
|
AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” |
Medicines for Europe |
03 Feb 2021 |
Health & Consumers |
|
Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks |
Medicines for Europe |
19 Jan 2021 |
Health & Consumers |
|
EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed |
Medicines for Europe |
15 Jan 2021 |
Health & Consumers |
|
EU pharma strategy success depends on access to generic, biosimilar and value added medicines |
Medicines for Europe |
25 Nov 2020 |
Health & Consumers |
|
European Health Union – first step to greater EU solidarity in health crisis situations |
Medicines for Europe |
11 Nov 2020 |
Health & Consumers |
